What is Ionis Pharmaceuticals's thereafter?

Ionis Pharmaceuticals (IONS) reported thereafter of $300K in Q4 2025.

Ionis Pharmaceuticals IONS Thereafter

Thereafter at other companies

BridgeBio PharmaBBIO

——

ViatrisVTRS

——

Other financials

Income statement

See full

Revenue$246.1M+87.0%

Gross profit$243.1M+86.8%

Operating income-$117.4M+20.0%

Net income-$92.5M+37.0%

EPS (diluted)-$0.56+39.8%

Balance sheet

See full

Cash & equivalents$173.4M-34.4%

Total debt$691.7M+334%

Total equity$491.4M+3.3%

Total assets$3.4B+22.6%

Cash flow

See full

Operating cash flow-$792.8M-426%

CapEx$21.8M+73.0%

Free cash flow-$814.6M-399%

Valuation

See full

Market cap$12.25B+159%

Enterprise value$12.77B+175%

P/S11.6×+5.0×

Profitability

See full

Gross margin98.4%-0.2pp

Operating margin-33.3%-11.0pp

Net margin-30.9%-10.5pp

FCF margin-77.4%+35.3pp

Returns & leverage

See full

Return on equity-67.6%-20.3pp

Debt / equity1.4×+1.1×

Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive.

The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's thereafter.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ionis Pharmaceuticals's thereafter?: Ionis Pharmaceuticals (IONS) reported thereafter of $300K in Q4 2025.